Mass balance study of [14C] rabeprazole following oral administration in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 11, 2006, Pages 557-565

  Setoyama, Tsutomu ^a   Drijfhout, W J ^b   van de Merbel, N C ^b   Humphries, T J ^c   Hasegawa, J ^d  

^a EISAI RESEARCH INSTITUTE   (United States)

^b PRA International USA   (Netherlands)

^c BAYER PHARMA AG   (Germany)

^d EISAI CO LTD   (Japan)

Author keywords

Mass balance; Pharmacokinetics; Proton pump inhibitor; Rabeprazole

Indexed keywords

ACETYLCYSTEINE DERIVATIVE; CARBON 14; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450 2C19; DRUG METABOLITE; RABEPRAZOLE; SULFIDE; SULFONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG LABELING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; ECG ABNORMALITY; FLUSHING; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; INDIVIDUALIZATION; ISOTOPE LABELING; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; RADIOACTIVITY; SOMNOLENCE;

EID: 33750876291     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44557     Document Type: Article

References (21)

1. Chiku S, Yoshimura T, Nakata H, Yuzuriha T Pharmacokinetics of a new benzimidazole sulfoxide derivative, E3810 (2): absorption, distribution, metabolism and excretion in rats. Xenobio Metab Dispos. 1994; 9: 612-627.
2. Furuta T, Ohashi K, Kosuge K, Ana XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T. CYP2C19 genotype status and effect of orneprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999; 65: 552-561.
3. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther. 2001; 70: 484-492.
4. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005; 20: 153-167.
5. Horn J. The proton pump inhibitors: Similarities and differences. Clin Ther. 2000; 22: 266-280.
6. Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther. 1999; 21: 691-701.
7. Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, Toyoki T. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mepherytoin 4′-hydroxylation. Clin Pharmacol Ther. 1995; 58. 155-164.
8. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther. 1999; 13 (Suppl 13). 27-36.
9. Keane WF, Swan SK, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure, J Clin Pharmacol. 1999; 39, 927-933.
10. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004; 95: 2-8.
11. Laurent AL, Merritt GJ, Setoyama T, Humphries TJ. Rabeprazole: pharmacokinetics and safety in the elderly. Clin Geriatr. 1999; 7: 27-33.
12. 14C] omeprazole in humans. Clin Pharmacol Ther. 1987; 42: 504-508.
13. Pichard-Garcia L, Whomsley R, Daujat M, Maurel P, Setoyama T Humphries TJ. Comparative effects of rabeprazole and omeprazole on the inducibility of cytochrome P450-1A and cytochrome P450-3A isoenzymes in human hepatocytes, and effects on cyclosporin metabolism in human liver microsomes. Clin Drug Invest. 2000; 20: 245-254.
14. Regårdh CG, Gabrielsson M, Hoffman KJ, Löfberg I, Skånberg I. Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scand J Gastroenterol. 1985; 20 (Suppl 108): 79-94.
15. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors. Drugs. 2003; 63: 2739-2754.
16. Setoyama T, Laurent A, Humphries TJ, Hasegawa J. Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. Int J Clin Pharmacol Ther. 2005; 43: 37-42.
17. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001; 15: 1929-1937.
18. VandenBranden M, Ring BJ, Binkley SN, Wrighton SA. Interaction of human liver microsomes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics. 1996; 6: 81-91.
19. Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, Shimamura Y, Morishita N. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994; 32: 466-473.
20. Yusuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiha K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status, Clin Pharmacol Ther. 1995; 58: 143-154.
21. Yasuda S, Higashi S, Murakami M, Tomono Y, Kawaguchi M. Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Int J Clin Pharmacol Ther. 1999; 37: 249-253.